Drug Profile
KCO 912
Alternative Names: KCO-912Latest Information Update: 14 Sep 2006
Price :
$50
*
At a glance
- Originator Novartis
- Class Small molecules
- Mechanism of Action Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 14 Sep 2006 Discontinued - Phase-II for Asthma (unspecified route)
- 22 Sep 2003 Phase-II clinical trials in Asthma (unspecified route)
- 19 Jul 2002 Clinical trials in Asthma (unspecified route)